Provided by Tiger Trade Technology Pte. Ltd.

Alto Neuroscience Inc

36.25
+1.975.75%
Post-market: 36.500.2500+0.69%19:30 EDT
Volume:867.97K
Turnover:30.76M
Market Cap:1.41B
PE:-15.22
High:36.99
Open:33.96
Low:33.52
Close:34.28
52wk High:36.99
52wk Low:3.41
Shares:38.87M
Float Shares:29.65M
Volume Ratio:1.94
T/O Rate:2.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3816
EPS(LYR):-2.1918
ROE:-49.17%
ROA:-26.79%
PB:6.43
PE(LYR):-16.54

Loading ...

Alto Neuroscience - Prices Offering of 3.78 Mln Shares at $26.48 Per Share

THOMSON REUTERS
·
Jul 13

Alto Neuroscience - Offering Expected to Raise Gross Proceeds of $100 Mln

THOMSON REUTERS
·
Jul 13

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

THOMSON REUTERS
·
Jul 13

Alto Neuroscience - to Accelerate and Expand Clinical Development of Alto-207 with Additional Planned Phase 3 Trial - SEC Filing

THOMSON REUTERS
·
Jul 13

Alto Neuroscience Estimates June 30 Cash, Equivalents and Restricted Cash at $244.2 Million

Reuters
·
Jul 13

H.C. Wainwright Remains a Buy on Alto Neuroscience, Inc. (ANRO)

TIPRANKS
·
Jun 25

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and BridgeBio Pharma (BBIO)

TIPRANKS
·
Jun 16

Alto Neuroscience posts investor presentation outlining precision psychiatry pipeline, biomarker-driven drug strategy

Reuters
·
Jun 15

Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol

TIPRANKS
·
Jun 15

Alto Neuroscience flags Nature Medicine trial showing pramipexole cuts anhedonia symptoms versus placebo

Reuters
·
Jun 15

Analysts’ Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Anixa Biosciences (ANIX)

TIPRANKS
·
Jun 11

Alto Neuroscience director Andrew Craig Miller files initial beneficial ownership statement

Reuters
·
May 30

Alto Neuroscience names Karuna Therapeutics founder Andrew Miller to board

Reuters
·
May 28

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.d. to Board of Directors

THOMSON REUTERS
·
May 28

BofA Securities Adjusts Price Target on Alto Neuroscience to $33 From $35

MT Newswires Live
·
May 22

Alto Neuroscience Is Maintained at Outperform by Baird

Dow Jones
·
May 19

JonesTrading Keeps Their Buy Rating on Alto Neuroscience, Inc. (ANRO)

TIPRANKS
·
May 15

Alto Neuroscience price target raised to $24 from $21 at Wedbush

TIPRANKS
·
May 15

Alto Neuroscience Is Maintained at Neutral by Wedbush

Dow Jones
·
May 14

Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained

TIPRANKS
·
May 14